Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2005-10-11
2010-12-28
Bristol, Lynn (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S139100, C514S012200, C530S387100
Reexamination Certificate
active
07858086
ABSTRACT:
The present invention provides new tumor-associated antigens, binding molecules that specifically bind to the antigens, nucleic acid molecules encoding the binding molecules, compositions comprising the binding molecules and methods of identifying or producing the binding molecules. The new tumor-associated antigen are expressed on cancer cells and binding molecules capable of specifically binding to the antigens can be used in the diagnosis, prevention and/or treatment of cancer.
REFERENCES:
patent: 2004/0101874 (2004-05-01), Ghosh et al.
patent: 2005/0026232 (2005-02-01), Yamamoto et al.
patent: 2005/0277173 (2005-12-01), Chin et al.
patent: WO 00/61180 (2000-10-01), None
patent: WO 03/087768 (2003-10-01), None
patent: WO 2004/043344 (2004-05-01), None
Sequence search aligment for SEQ ID No. 6 and Ghosh et al (US20040101874; USAN 10/408,765) (pp. 1-2) (Dec. 8, 2008).
Sequence search alignment for instant claimed SEQ ID No. 6 vs WO2003087768 (pp. 1-2; Apr. 8, 2009).
Dufner (Trends Biotechnol. 24(11):523-29 (2006)).
MacCallum et al. (J. Mol. Biol. (1996) 262:732-745).
De Pascalis et al. The Journal of Immunology (2002) 169, 3076-3084.
Casset et al. (2003) BBRC 307, 198-205.
Vajdos et al. (2002) J. Mol. Biol. 320, 415-428.
Holm et al (2007) Mol. Immunol. 44: 1075-1084.
Chen et al. J. Mol. Bio. (1999) 293, 865-881.
Wu et al. J. Mol. Biol. (1999) 294, 151-162.
Brummell et al. (Biochemistry 32:1180-1187 (1993)).
Kobayashi et al. (Protein Engineering 12:879-844 (1999)).
Burks et al. (PNAS 94:412-417 (1997)).
Coleman (Research in Immunol. 145:33-36 (1994)).
Jang et al. (Molec. Immunol. 35:1207-1217 (1998)).
Brorson et al. (J. Immunol. 163:6694-6701 (1999)).
Brandt et al., Aberrant Expression of CD19 as a Marker of Monocytic Lineage in Acute Myelogenous Leukemia, American Journal of Clinical Pathology, 1997, pp. 283-291, vol. 107, No. 3.
Geuijen et al., A proteomic approach to tumour target identification using phage display, affinity purification and mass spectometry, European Journal of Cancer, 2005, pp. 178-187, vol. 41.
Myers et al., Large Scale Manufacturing of TXU (Anti-CD7)- Pokeweed Antiviral Protein (PAP) Immunoconjugate for Clinical Trials, Oct. 1997, pp. 275-302, vol. 27.
Streuli et al., Expression of the receptor-linked protein tyrosine phosphatase LAR: proteolytic cleavage and shedding of the CAM-like extracellular region, The EMBO Journal, 1992, pp. 897-907, vol. 11. No. 3.
International Preliminary Report on Patentability, PCT/EP2005/055163, dated Dec. 7, 2006.
De Kruif Cornelis Adriaan
Geuijen Cecilia Anna Wilhelmina
Bristol Lynn
Crucell Holland B.V.
TraskBritt P.C.
LandOfFree
Binding molecules for treatment and detection of cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Binding molecules for treatment and detection of cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Binding molecules for treatment and detection of cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4199782